HeartSciences Announces Pilot Study Results published in launch edition of European Heart Journal-Digital Health

Heart disease is a global pandemic affecting at least 26 million people worldwide and continues to increase in prevalence due to increasing life expectancy in the general population. More effective front-line tools are needed that can assist in identifying patients earlier while also lowering costs for health systems around the world. The article is titled “Prediction of coronary artery calcium scoring from surface electrocardiogram in atherosclerotic cardiovascular disease: a pilot study”. The study evaluated the feasibility of MyoVista Technology to assist in predicting abnormal calcium scores.

HeartSciences Announces Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Study demonstrates MyoVista® wavECG™ ability to cost-effectively detect LV Dysfunction   SOUTHLAKE, Texas, August 18, 2020 – HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced today the results of a multicenter prospective study conducted at 4 centers in North America enrolling a total of 1,202 subjects. The study […]

MedTech Strategist Names HeartSciences as Start-Up to Watch

HeartSciences: AI Improves Frontline Risk Stratification for Heart Diseases
https://heartsciences.com/wp-content/uploads/2018/06/MedTechStrategist-Heartsciences-AI-Improves-Risk-Stratification.pdf

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today that Peter W. Macfarlane has joined its board of clinical advisors.

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

“These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices”

HeartSciences Announces Poster Presentation at the 2018 American College of Cardiology Scientific Sessions

Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets Date: Sunday, March 11, 2018 at 3:45 p.m. Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B Poster: 1238-107 HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational […]

HeartSciences, a Fierce Innovation Award Finalist, will present at Biotech Showcase Events in San Francisco on January 9 and 10, 2018

Southlake, Texas – January 3, 2018 – HeartSciences, a medical device company recently selected as a finalist for the Digital Health Solution category of Fierce Innovation Awards will be presenting in San Francisco at the BioTech Showcase.  Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10.00am, at the Parc 55 Hotel.

CTV News Ontario, Canada – Dr. Wadea Tarhuni and HeartSciences MyoVista Cardiac Testing Device

HeartSciences and MyoVista Cardiac Testing Device   http://windsor.ctvnews.ca/video?clipId=1243217&binId=1.1143900&playlistPageNum=1  

HeartSciences gets green light to sell next-gen ECG in EU

HeartSciences has started selling its MyoVista electrocardiograph (ECG) in Europe after picking up a CE mark. The device is designed to enable early detection of artery disease by visualizing energy distribution during cardiac cycles. Traditional ECGs detect and display the electrical signals the heart produces when it beats. The low cost and safety of the […]